PHILADELPHIA, May 17, 2017 /PRNewswire/ -- Current financing options as well as well as trends in drug pricing and reimbursement will be key discussion topics on the agenda when The Association of Bioscience Financial Officers (ABFO) 2017 National Conference kicks off in Philadelphia later this month. Slated for May 30-June 2 at the Logan Hotel, the meeting is expected to draw more than 150 controllers, accounting executives and CFOs with U.S. companies that focus on the development of drugs, medical devices and diagnostics.
The 2017 program is comprised of several keynote presentations from high-profile executives, including Joe Quinlan, managing director & chief market strategist, U.S. Trust, Bank of America, Private Wealth Management; Dominic J. Caruso, executive vice president, CFO, Johnson & Johnson; and Michael Smerconish, host, "Smerconish" CNN, "The Michael Smerconish Program," SiriusXM Radio. Rounding out the line-up is Jeff Marrazzo, CEO of the host city-based Spark Therapeutics.
Program session topics designed to generate discussion and equip participants with practical information for use in their finance roles are:
- The convergence of science and technology
- Business issues at each stage of a company's development
- Financing alternatives
- Challenges in managing the R&D portfolio
- Compensation practices
- Investor and public relations practices
- Pricing and reimbursement trends
- Revenue recognition
- Buy-side views
- Board position responsibilities
- Cybersecurity risk mitigation
ABFO National Conference attendees can earn up to 18 hours of continuing professional education (CPE) credits through participation in the two-and-a-half days of programs while networking with their industry peers. An annual highlight is ABFO's "mystery event," an evening activity designed to bring attendees together for an over-the-top local experience that has been a hallmark of the organization's meeting since the first one in 1990. Click here to see the complete program.
"This meeting is ideal for all levels of finance executives looking for learning and networking opportunities exclusive to the bioscience industry," said Louis Arcudi III, senior vice president of operations, chief financial officer, Idera Pharmaceuticals Inc., and conference co-chair. "We encourage those who have not experienced ABFO to join us in Philadelphia for a program designed for financial officers by financial officers. It is a unique conference."
Michael Celano, chief financial officer, Recro Pharma Inc., and conference co-chair, added: "The diversity of company stage and type represented will lead to well-rounded discussions. This is ABFO's hallmark, and we look forward to hosting the conference in Philadelphia. Limited seats are still available with registration easy to complete online."
The 2017 ABFO National Conference is sponsored by Aon, Bank of America Merrill Lynch, Cooley, EY, Merrill Corporation, Oxford Finance and R&D Logic. Russo Partners is a conference supporter.
Formed in 1989, the Association of Bioscience Financial Officers has 11 chapters that serve as forums for the exchange of information about the industry and networking. Regional chapters are based in top bioscience hubs to allow for face-to-face meetings and discussion of hot topics of interest to bioscience financial officers. The regional chapters meet annually at the ABFO National Conference for extended networking. For more information, visit http://www.abfointernational.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/current-financing-options-drug-pricing-and-reimbursement-on-agenda-at-association-of-bioscience-financial-officers-national-conference-300459135.html
SOURCE Association of Bioscience Financial Officers